BioStem Technologies reports developments tied to its regenerative medicine business, which develops, manufactures and commercializes perinatal tissue allograft products used by clinicians across wound care and other specialties. Company updates commonly cover financial results, conference calls, clinical research presentations, and product portfolio activity involving brands such as Neox, Clarix, VENDAJE and American Amnion.
BioStem news also includes governance and compliance appointments, board changes, audited financial statement publication, and integration of completed asset acquisitions that expand its surgical and wound-care product offerings. Its disclosures describe proprietary BioRetain, CryoTek and SteriTek processing technologies, AATB-accredited quality systems, and operations aligned with current Good Tissue Practices and current Good Manufacturing Processes.
BioStem Technologies (BSEM) has received a U.S. patent and additional patent allowances covering its placental and umbilical cord tissue technologies.
The USPTO issued Patent No. 12,648,969 for sterile human placental allografts and three notices of allowance covering placental wound treatment, micronized tissue combinations for wound healing, and umbilical cord extract for joint inflammation. Mexico’s patent authority issued another notice of allowance for sterile placental allografts. The allowances concern applications, not issued patents.
BioStem plans to continue committing resources to expanding and defending its patent estate in the U.S. and internationally.
BioStem Technologies (BSEM) entered definitive agreements for a private placement expected to raise approximately $3 million in gross proceeds. The Nasdaq at-the-market transaction includes 735,296 common shares with associated Series A and Series B warrants at $4.08 per share and associated warrants. Each warrant series covers up to 735,296 additional shares.
The warrants have a $3.83 exercise price and are exercisable immediately upon issuance. Series A expires five years after the resale registration statement becomes effective; Series B expires twenty-four months after that date. BioStem expects closing on or about September 30, 2026, subject to customary closing conditions. Gross proceeds are before placement agent fees and other offering expenses. H.C. Wainwright & Co. is the exclusive placement agent. BioStem intends to use net proceeds for working capital and general corporate purposes.
BioStem Technologies (BSEM) entered into a Committed Equity Facility of up to $40 million with Roth Principal Investments. The facility permits, but does not require, BioStem to sell common shares to Roth via private placements at the company’s discretion, once a resale registration statement is filed with and declared effective by the SEC.
Issuances are subject to Nasdaq rules, including an Exchange Cap limiting new shares to 19.99% of shares outstanding before the Purchase Agreement, unless shareholder approval is obtained or pricing meets Nasdaq’s minimum price test. BioStem plans to use any net proceeds for working capital and general corporate purposes and is not obligated to draw the full amount.
BioStem Technologies (BSEM) has added its VENDAJE® and VENDAJE AC® placental-derived wound care allografts to existing contracts with Vizient and Premier, two of the largest U.S. Group Purchasing Organizations, making both products available for hospital ordering effective immediately.
This marks the first GPO contract coverage for VENDAJE and VENDAJE AC and extends BioStem’s hospital channel for its BioRetain® wound care line. Vizient serves more than 5,000 hospitals and Premier more than 4,000. Both products are minimally manipulated dehydrated tissue allografts manufactured using BioStem’s proprietary BioRetain process.
BioStem Technologies (BSEM)/b) announced that its management will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY, with conference participation scheduled for Monday, September 14.A prerecorded fireside chat will be available starting Friday, September 11, 2026, at 7:00 AM ET, and interested investors can access live and archived webcasts through the investors section of BioStem’s website at ir.biostemtechnologies.com. BioStem develops, manufactures, and commercializes perinatal tissue allograft products using its proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, and its portfolio includes Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.
BioStem Technologies (Nasdaq: BSEM) announced that management will present at the Sidoti MicroCap Virtual Conference on Wednesday, August 19, 2026, at 10:45 AM ET. A live and archived webcast of the presentation will be available in the investors section of the company’s website.
BioStem develops, manufactures and commercializes perinatal tissue allograft products using its proprietary BioRetain, CryoTek and SteriTek processing technologies. Its allografts are used across multiple clinical specialties. The company highlights a growing product portfolio, expanding clinical research initiatives, a national commercial footprint, and accreditation by the Association for Advancing Tissue and Biologics, operating under cGTP and cGMP standards.
BioStem Technologies (Nasdaq: BSEM) reported Q2 2026 net revenue of $7.9 million, up 29% sequentially from $6.1 million but down from $11.0 million in Q2 2025. Revenue was driven mainly by Neox and Clarix products, with hospital revenue of $6.7 million and physician office revenue of $1.1 million.
Gross profit was $4.8 million with a 61% margin, flat sequentially but below 94% a year ago. Operating expenses rose to $13.2 million, leading to a GAAP net loss of $9.0 million and Adjusted EBITDA loss of $4.6 million. Cash and equivalents fell to $7.0 million. The company completed a $2.5 million private placement, resolved $5.3 million of debt, uplisted to the Nasdaq Capital Market on August 7, 2026, and, according to BioStem, raised full-year 2026 revenue guidance to $26–29 million from $25–29 million.
BioStem Technologies (BSEM) announced that Nasdaq has approved the company’s common stock for listing on The Nasdaq Capital Market. Trading is expected to commence on August 7, 2026 under the unchanged ticker symbol BSEM.
According to BioStem, the uplisting marks a key milestone in its strategy to strengthen its foundation and operations. Shareholders are not required to take any action due to the listing change. BioStem develops, manufactures, and commercializes perinatal tissue allograft products using its proprietary BioRetain®, CryoTek® and SteriTek® technologies.
BioStem Technologies (OTC: BSEM) will release its second quarter 2026 financial results on Wednesday, August 12, 2026, followed by a conference call and webcast at 4:30 PM ET. The event will feature an overview of the quarter from BioStem management.
According to the company, investors can join via North America toll-free line (800) 715-9871, international line +1 (646) 307-1963, using Conference ID 9695874, or through the webcast at https://events.q4inc.com/attendee/199151484. BioStem focuses on perinatal tissue allograft products and leverages its proprietary BioRetain®, CryoTek® and SteriTek® technologies across brands including Neox®, Clarix®, VENDAJE® and American Amnion™.
BioStem Technologies (OTC:BSEM) filed a Form 10 registration statement with the U.S. SEC to register its common stock under the Exchange Act and reaffirmed its plan to seek a Nasdaq listing. The Form 10 is not yet effective, and the stock will continue trading on the OTC market until any Nasdaq uplisting.